As HIV has been converted to a chronic disease with successful antiretroviral therapy, there is a pressing need to understand better the pathogenesis of residual inflammation that is linked to the non-infectious complications of treated HIV including cardiovascular and venous thromboembolic events. Innate immune activation appears central in this process and could be amenable to novel therapeutic interventions.